REFERENCES
1. Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68:335-52.
2. Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine. 2020;1:85-107.
3. Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis. 2017;49:471-83.
4. Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Future Med Chem. 2019;11:2171-92.
5. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2020; doi: 10.1136/gutjnl-2020-323082.
6. Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9:65-90.
7. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
8. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44-52.
9. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19:359-66.
10. Loria P, Marchesini G, Nascimbeni F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis. 2014;232:99-109.
11. Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol. 2006;44:190-6.
12. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.
13. Weber KS, Simon MC, Strassburger K, et al. GDS Group. Habitual fructose intake relates to insulin sensitivity and Fatty Liver Index in recent-onset type 2 diabetes patients and individuals without diabetes. Nutrients. 2018;10:774.
14. Leone A, Battezzati A, Bedogni G, et al. Sex- and age-related differences in the contribution of ultrasound-measured visceral and subcutaneous abdominal fat to fatty liver index in overweight and obese caucasian adults. Nutrients. 2019;11:3008.
15. Klisic A, Kavaric N, Ninic A. Predictive values of serum uric acid and alanine-aminotransferase for Fatty Liver Index in Montenegrin population. J Med Biochem. 2019;38:407-17.
16. Nivukoski U, Niemelä M, Bloigu A, et al. Combined effects of lifestyle risk factors on fatty liver index. BMC Gastroenterol. 2020;20:109.
17. Tien NV, Arisawa K, Uemura H, Imaeda N, Goto C, Katsuura-Kamano S. Association between nutrient patterns and fatty liver index: baseline survey of the Japan Multi-Institutional Collaborative Cohort Study in Tokushima, Japan. J Epidemiol. 2021; doi: 10.2188/jea.JE20200447.
18. Bertolotti M, Lonardo A, Mussi C, et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol. 2014;20:14185-204.
19. Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on clinical aspects and implications for practice and translational research. J Clin Med. 2020;9:1278.
20. Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68:1063-75.
21. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10.
22. Foschi FG, Conti F, Domenicali M, et al. External validation of surrogate indices of fatty liver in the general population: the Bagnacavallo study. J Clin Med. 2021;10:520.
23. Klisic A, Isakovic A, Kocic G, et al. Relationship between oxidative stress, inflammation and dyslipidemia with Fatty Liver Index in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2018;126:371-8.
24. Chen LD, Huang JF, Chen QS, et al. Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome. Chin Med J (Engl). 2019;132:2670-6.
25. Hsu CL, Wu FZ, Lin KH, et al. Role of Fatty Liver Index and metabolic factors in the prediction of nonalcoholic fatty liver disease in a lean population receiving health checkup. Clin Transl Gastroenterol. 2019;10:1-8.
26. Rabbitt LA, McNally M, Reynolds L, et al. A prospective cohort study of the use of the fatty liver index and Fibroscan to determine the prevalence of fatty liver disease in an Irish population. Eur J Gastroenterol Hepatol. 2020; doi: 10.1097/MEG.0000000000001951.
27. Chen LW, Huang PR, Chien CH, Lin CL, Chien RN. A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease. J Formos Med Assoc. 2020;119:173-81.
28. Motamed N, Faraji AH, Khonsari MR, et al. Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: a population-based study of northern Iran. Clin Nutr. 2020;39:468-74.
29. Castellana M, Donghia R, Guerra V, et al. Performance of Fatty Liver Index in identifying non-alcoholic fatty liver disease in population studies. a meta-analysis. J Clin Med. 2021;10:1877.
30. Steyerberg EW. Clinical prediction models. Cham: Springer International; 2019.
31. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1209-22.
32. Khang AR, Lee HW, Yi D, Kang YH, Son SM. The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010-2011. Diabetes Metab Syndr Obes. 2019;12:181-90.
33. Lee HJ, Jo HN, Kim YH, Kim SC, Joo JK, Lee KS. Predictive value of lipid accumulation product, fatty liver index, visceral adiposity index for metabolic syndrome according to menopausal status. Metab Syndr Relat Disord. 2018;16:477-82.
34. Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int. 2012;32:1242-52.
35. Ballestri S, Nascimbeni F, Lugari S, Lonardo A, Francica G. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Rev Gastroenterol Hepatol. 2019;13:667-81.
36. Ballestri S, Tana C, Di Girolamo M, et al. Semi-quantitative ultrasonographic evaluation of NAFLD. Curr Pharm Des. 2020;26:3915-27.
37. Xavier SA, Monteiro SO, Arieira CM, et al. US-FLI score - is it possible to predict the steatosis grade with an ultrasonographic score? Mol Genet Metab. 2021;132:204-9.
38. Qiu J, Zhou Z, Wang J, et al. Associations between fatty liver index and asymptomatic intracranial vertebrobasilar stenosis in Chinese population. PLoS One. 2017;12:e0187502.
39. Cicero AFG, Gitto S, Fogacci F, et al. Brisighella Heart Study Group Medical and Surgical Sciences Dept, University of Bologna. Fatty liver index is associated to pulse wave velocity in healthy subjects: data from the Brisighella Heart Study. Eur J Intern Med. 2018;53:29-33.
40. Olubamwo OO, Virtanen JK, Voutilainen A, Kauhanen J, Pihlajamäki J, Tuomainen TP. Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction. Eur J Gastroenterol Hepatol. 2018;30:1047-54.
41. Olubamwo OO, Virtanen JK, Pihlajamaki J, Mantyselka P, Tuomainen TP. Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort. BMJ Open. 2019;9:e031420.
42. Roh JH, Park JH, Lee H, et al. Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea. BMC Cardiovasc Disord. 2020;20:204.
43. Kim JH, Moon JS, Byun SJ, et al. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. Cardiovasc Diabetol. 2020;19:51.
44. Iwasaki Y, Shiina K, Matsumoto C, et al. Correlation of the fatty liver index with the pathophysiological abnormalities associated with cardiovascular risk markers in Japanese men without any history of cardiovascular disease: comparison with the fibrosis-4 score. J Atheroscler Thromb. 2021;28:524-34.
45. Li X, Heiskanen JS, Ma H, et al. Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. J Hypertens. 2021;39:961-9.
46. Zou B, Yeo YH, Cheung R, Ingelsson E, Nguyen MH. Fatty liver index and development of cardiovascular disease: findings from the UK Biobank. Dig Dis Sci. 2021;66:2092-100.
47. Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig. 2015;107:10-6.
48. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589-600.
49. Bedogni G, Gastaldelli A, Foschi FG. Fatty liver, cardiometabolic disease and mortality. Curr Opin Lipidol. 2020;31:27-31.
50. Ballestri S, Mantovani A, Baldelli E, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics (Basel). 2021;11:98.
51. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936-44.
52. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:5888.
53. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70:962-9.
54. Matsushita Y, Hasegawa Y, Takebe N, et al. Serum C-X-C motif chemokine ligand 14 levels are associated with serum C-peptide and fatty liver index in type 2 diabetes mellitus patients. J Diabetes Investig. 2021;12:1042-9.
55. Hirata A, Sugiyama D, Kuwabara K, et al. Fatty liver index predicts incident diabetes in a Japanese general population with and without impaired fasting glucose. Hepatol Res. 2018;48:708-16.
56. Franch-Nadal J, Caballeria L, Mata-Cases M, et al. PREDAPS Study Group. Fatty liver index is a predictor of incident diabetes in patients with prediabetes: the PREDAPS study. PLoS One. 2018;13:e0198327.
57. Olubamwo OO, Virtanen JK, Pihlajamaki J, Tuomainen TP. Association of fatty liver index with risk of incident type 2 diabetes by metabolic syndrome status in an Eastern Finland male cohort: a prospective study. BMJ Open. 2019;9:e026949.
58. Wargny M, Smati S, Pichelin M, et al. Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. PLoS One. 2019;14:e0221524.
59. Movahedian M, Rahmani J, Hashemi Nazari SS, Mohamadi S, Naik G, Hekmatdoost A. Fatty liver index and risk of diabetes incidence: a systematic review and dose-response meta-analysis of cohort studies. Prim Care Diabetes. 2020;14:577-83.
60. Niu Z, Wu Q, Sun L, et al. Circulating glycerolipids, Fatty Liver Index, and incidence of type 2 diabetes: a prospective study among Chinese. J Clin Endocrinol Metab. 2021;106:2010-20.
61. Busquets-Cortés C, Bennasar-Veny M, López-González ÁA, Fresneda S, Abbate M, Yáñez AM. Utility of Fatty Liver Index to predict reversion to normoglycemia in people with prediabetes. PLoS One. 2021;16:e0249221.
62. Samuel VT, Shulman GI. Nonalcoholic fatty liver disease, insulin resistance, and ceramides. N Engl J Med. 2019;381:1866-9.
63. Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol. 2019;56:385-96.
64. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537-64.
65. Sun K, Lin D, Li F, et al. Fatty liver index, albuminuria and the association with chronic kidney disease: a population-based study in China. BMJ Open. 2018;8:e019097.
66. Takahashi S, Tanaka M, Furuhashi M, et al. Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. Sci Rep. 2021;11:8606.
67. Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006;44:1196-207.
68. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol. 2009;6:236-47.
69. Liebe R, Esposito I, Bock HH, et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021;74:1455-71.
70. Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. Int J Mol Sci. 2019;20:2841.
71. Liu CC, Huang SP, Hsieh TJ, et al. Fatty liver index is associated with the risk of testosterone deficiency in aging men without metabolic syndrome. Andrology. 2021;9:863-72.
72. Ahn SH, Seo DH, Kim SH, Nam MS, Hong S. The relationship between fatty liver index and bone mineral density in Koreans: KNHANES 2010-2011. Osteoporos Int. 2018;29:181-90.
73. Lonardo A, Roncucci L. The "obese liver" and gastrointestinal cancer risk. Transl Gastroenterol Hepatol. 2020;5:44.
74. Ze EY, Kim BJ, Jun DH, Kim JG, Kang H, Lee DY. The Fatty Liver Index: a simple and accurate predictor of colorectal adenoma in an average-risk population. Dis Colon Rectum. 2018;61:36-42.
75. Choi YJ, Lee DH, Han KD. Association between high fatty liver index and development of colorectal cancer: a nationwide cohort study with 21,592,374 Korean. Korean J Intern Med. 2020;35:1354-63.
76. Park JH, Choi IS, Han KD, Park H, Kim KH, Kim JS. Association between fatty liver index and risk of breast cancer: a nationwide population-based study. Clin Breast Cancer. 2020;20:e450-7.
77. Liu Y, Zhong GC, Tan HY, Hao FB, Hu JJ. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep. 2019;9:11124.
78. Lerchbaum E, Pilz S, Grammer TB, et al. The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. Nutr Metab Cardiovasc Dis. 2013;23:1231-8.
79. Setti M, Voutilainen A, Tuomainen TP. Renal hyperfiltration, fatty liver index, and the hazards of all-cause and cardiovascular mortality in Finnish men. Epidemiol Health. 2021;43:e2021001.
80. Lee CH, Han KD, Kim DH, Kwak MS. The repeatedly elevated fatty liver index is associated with increased mortality: a population-based cohort study. Front Endocrinol (Lausanne). 2021;12:638615.
81. Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. A multi-strain probiotic reduces the Fatty Liver Index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. J Gastrointestin Liver Dis. 2018;27:41-9.
82. Drinda S, Grundler F, Neumann T, et al. Effects of periodic fasting on fatty liver index-a prospective observational study. Nutrients. 2019;11:2601.
83. Besutti G, Bonilauri L, Manicardi E, et al. Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. Diabetes Res Clin Pract. 2021;177:108882.
84. Lonardo A, Bellentani S, Argo CK, et al. Non-alcoholic Fatty Liver Disease Study Group. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47:997-1006.
